Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01348659
Other study ID # R09246M
Secondary ID 2010-019352-42
Status Completed
Phase Phase 4
First received May 2, 2011
Last updated May 4, 2012
Start date May 2011
Est. completion date May 2012

Study information

Verified date May 2012
Source Tampere University Hospital
Contact n/a
Is FDA regulated No
Health authority Finland: Finnish Medicines Agency
Study type Interventional

Clinical Trial Summary

The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir of the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight and extracellular water from baseline to the first postoperative morning.


Description:

Cardiac surgery and cardiopulmonary bypass (CPB) cause fluid retention in the body. Both dilution of serum proteins and destruction of vascular endothelial glycocalyx cause extravasation of the fluids. We cannot avoid this phenomenon but we can try to restore the excess fluid into the intravascular space where it can be excreted via the kidneys.

Hypertonic saline (HS) creates an osmotic gradient across the cellular membrane, causing a fluid shift from the intracellular space into the extracellular space and from the extravascular space into the intravascular space. The intravascular hypertonic benefit is short-lasting as a result of redistribution of fluid between the intravascular and interstitial spaces. The effect can be lengthened by adding colloid component into the solution.

The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir of the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight and extracellular water from baseline to the first postoperative morning. Secondary endpoints are the need of fluids and diuretic medication during the perioperative period.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- male gender and no need for pulmonary artery catheter (pulmonary hypertension or left ventricular ejection fraction < 40%).

Exclusion Criteria:

- chronic hyponatremia and significant renal dysfunction.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
7.2% NaCl/hydroxyethylstarch
250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
NaCl 0.9%
250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.

Locations

Country Name City State
Finland Tampere University Hospital Heart Center Tampere

Sponsors (2)

Lead Sponsor Collaborator
Kati Järvelä Finnish Cultural Foundation

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in extracellular water from baseline to the first postoperative morning. Perioperative fluid balance will be assessed by measuring changes in body weight and extracellular water from baseline to the first postoperative morning. 24h No
Secondary Need of fluids during the day of surgery. Need of fluids and diuretic medication during the day of surgery until the first postoperative morning will be recorded. 24h No
See also
  Status Clinical Trial Phase
Completed NCT03917446 - Volume Responsiveness Assesment After Propofol.
Not yet recruiting NCT01456702 - Risk Stratification and Goal-directed Volume Therapy N/A